Atlas One · Host Biology · Scale 03 — Molecular

MET

Receptor tyrosine kinase for hepatocyte growth factor (HGF); MET amplification drives EGFR TKI resistance in NSCLC (~5-15% of acquired resistance); MET exon 14 skipping (~3-4% NSCLC) is a primary driver; capmatinib and tepotinib are approved MET inhibitors in METex14 NSCLC.

Also known as: MET, c-MET, HGFR, hepatocyte growth factor receptor, METex14, MET exon 14 skipping, MET amplification

Scale 03 — MolecularScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
met

MET

Receptor tyrosine kinase for hepatocyte growth factor (HGF); MET amplification drives EGFR TKI resistance in NSCLC (~5-15% of acquired resistance); MET exon 14 skipping (~3-4% NSCLC) is a primary driver; capmatinib and tepotinib are approved MET inhibitors in METex14 NSCLC.

Entry Metadata

FieldValue
IDmet
NameMET
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale03-molecular

Cross-Atlas Connections

connects-toKras connects-toMtor connects-toVegf connects-toEgfr

Sources